Corium International, Inc. (NASDAQ:CORI) major shareholder Healthcare Master Fun Broadfin sold 150,000 shares of Corium International stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $11.05, for a total transaction of $1,657,500.00. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Wednesday, October 4th, Healthcare Master Fun Broadfin sold 218,100 shares of Corium International stock. The shares were sold at an average price of $11.01, for a total transaction of $2,401,281.00.

Corium International, Inc. (NASDAQ:CORI) opened at $11.21 on Friday. The company has a quick ratio of 6.80, a current ratio of 7.04 and a debt-to-equity ratio of 1.89. Corium International, Inc. has a 1-year low of $2.67 and a 1-year high of $11.37.

Corium International (NASDAQ:CORI) last released its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.13). The firm had revenue of $8.11 million during the quarter, compared to analysts’ expectations of $8.71 million. Corium International had a negative return on equity of 673.17% and a negative net margin of 145.60%. equities analysts forecast that Corium International, Inc. will post -1.74 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “Healthcare Master Fun Broadfin Sells 150,000 Shares of Corium International, Inc. (CORI) Stock” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this piece on another publication, it was copied illegally and republished in violation of US and international trademark & copyright legislation. The original version of this piece can be read at https://www.watchlistnews.com/healthcare-master-fun-broadfin-sells-150000-shares-of-corium-international-inc-cori-stock/1679655.html.

CORI has been the topic of several research reports. BidaskClub lowered shares of Corium International from a “hold” rating to a “sell” rating in a report on Friday, August 11th. Needham & Company LLC reaffirmed a “buy” rating and issued a $13.00 price target on shares of Corium International in a report on Sunday, September 17th. ValuEngine raised shares of Corium International from a “sell” rating to a “hold” rating in a report on Friday, September 1st. Zacks Investment Research raised shares of Corium International from a “hold” rating to a “buy” rating and set a $12.00 price target on the stock in a report on Tuesday, October 3rd. Finally, Jefferies Group LLC set a $10.00 price target on shares of Corium International and gave the stock a “buy” rating in a report on Sunday, October 29th. One analyst has rated the stock with a sell rating, two have given a hold rating and seven have issued a buy rating to the company. Corium International has a consensus rating of “Buy” and a consensus price target of $13.00.

Institutional investors and hedge funds have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its holdings in shares of Corium International by 161.8% during the second quarter. Bank of New York Mellon Corp now owns 66,160 shares of the biopharmaceutical company’s stock valued at $494,000 after buying an additional 40,891 shares during the last quarter. EAM Investors LLC purchased a new stake in shares of Corium International during the second quarter valued at $563,000. Stonepine Capital Management LLC purchased a new stake in shares of Corium International during the second quarter valued at $3,085,000. California State Teachers Retirement System purchased a new stake in shares of Corium International during the second quarter valued at $263,000. Finally, State Street Corp purchased a new stake in shares of Corium International during the second quarter valued at $1,840,000. 90.14% of the stock is currently owned by hedge funds and other institutional investors.

Corium International Company Profile

Corium International, Inc is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease.

Insider Buying and Selling by Quarter for Corium International (NASDAQ:CORI)

Receive News & Ratings for Corium International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corium International Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.